Oryzon Genomics a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an upda...
Read more
Los estudios en microgravedad juegan un papel fundamental para el desarrollo de las innovaciones biotecnológicos, pero suponen un elevado coste medioambiental.
Read more
Study provides clinical scales and thresholds for patient selection in future clinical trials, based on aggressiveness, cognition, and behavioral traits
Read more
Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)
Read more
Oryzon Genomics, S.A, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fou...
Read more
The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (A...
Read more
Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities
Read more
Oryzon Genomics, S.A. announced today that the first patient has been dosed in an investigator-initiated Phase I dose-finding trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in c...
Read more
Oryzon Genomics S.A., compañía biofarmacéutica de fase clínica centrada en la epigenética para el desarrollo de terapias para enfermedades con importantes necesidades médicas no resueltas, se co...
Read more
Oryzon Genomics announced today that the first patient has been dosed in a Phase I dose-finding clinical trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with venet...
Read more
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...
Read more
Oryzon Genomics announced today that the Russian Patent Office has issued a “Decision to grant” communication for Oryzon’s Russian patent application RU2021130172. This patent relates to vafidem...
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The results show that adenocarcinoma exhibits much more active and fun...
